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Lipid raft-mediated Akt signaling as a therapeutic target in mantle
cell lymphoma
M Reis-Sobreiro1, G Roue´2, A Moros2, C Gajate1, J de la Iglesia-Vicente1, D Colomer2 and F Mollinedo1
Recent evidence shows that lipid raft membrane domains modulate both cell survival and death. Here, we have found that the
phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway is present in the lipid rafts of mantle cell lymphoma (MCL) cells, and this
location seems to be critical for full activation and MCL cell survival. The antitumor lipids (ATLs) edelfosine and perifosine target
rafts, and we found that ATLs exerted in vitro and in vivo antitumor activity against MCL cells by displacing Akt as well as key
regulatory kinases p-PDK1 (phosphatidylinositol-dependent protein kinase 1), PI3K and mTOR (mammalian TOR) from lipid rafts.
This raft reorganization led to Akt dephosphorylation, while proapoptotic Fas/CD95 death receptor was recruited into rafts. Raft
integrity was critical for Ser473 Akt phosphorylation. ATL-induced apoptosis appeared to correlate with the basal Akt
phosphorylation status in MCL cell lines and primary cultures, and could be potentiated by the PI3K inhibitor wortmannin, or
inhibited by the Akt activator pervanadate. Classical Akt inhibitors induced apoptosis in MCL cells. Microenvironmental stimuli, such
as CD40 ligation or stromal cell contact, did not prevent ATL-induced apoptosis in MCL cell lines and patient-derived cells. These
results highlight the role of raft-mediated PI3K/Akt signaling in MCL cell survival and chemotherapy, thus becoming a new target
for MCL treatment.
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INTRODUCTION
Mantle cell lymphoma (MCL) is a B cell-derived neoplasia that
constitutes B6% of all non-Hodgkin lymphomas, and is char-
acterized by the chromosomal translocation t(11;14)(q13;q32),
leading to aberrant overexpression of cyclin D1.1,2 In addition to
this initial oncogenic event, MCL may carry a high number of
secondary chromosomal and molecular alterations that inﬂuence
the aggressive behavior of this neoplasm and a poor survival
outcome.1,2 Although conventional chemotherapy induces high-
remission rates, relapse within a few years is common,
contributing to a median survival of 5–7 years.3
Several signaling pathways are deregulated in MCL cells
including the constitutive activation of the phosphatidylinositol-
3-kinase (PI3K)/Akt pathway, which mediates the effects of a
variety of extracellular signals and is crucial for the maintenance
and proliferation of MCL cells,4,5 thus attracting great interest as a
possible therapeutic target. PI3K is activated by a wide range of
tyrosine kinase growth factor receptors, and is the major activator
of Akt, having a central role in fundamental biological processes
including cell growth, proliferation, migration and survival,
through phosphorylation of a plethora of substrates.4,6 Akt is a
protein kinase that belongs to the AGC family of serine/threonine
kinases and has three conserved domains, namely: pleckstrin
homology domain (PH), which binds phosphoinositides with
high afﬁnity, as well as catalytic and regulatory domains.7
Akt suppresses apoptosis by direct phosphorylation of
proapoptotic proteins such as Bad and pro-caspase-9.7 PI3K phos-
phorylates phosphatidylinositol-4,5-bisphosphate to generate
phosphatidylinositol-3,4,5-trisphosphate, which binds to Akt PH
domain and phosphatidylinositol-dependent protein kinase 1
(PDK1), recruiting them to the membrane. Once in the membrane,
Akt is phosphorylated at two key residues, Thr308 and Ser473.8
Thr308 site is localized in the activation loop and is
phosphorylated by PDK1, whereas Ser473 is localized in the
C-terminal hydrophobic motif and is phosphorylated by PDK2.8
Mammalian TOR (mTOR) has been suggested as the main
candidate for PDK2, but DNA-PK, ILK or even Akt itself through
autophosphorylation have also been proposed to act as PDK2.8,9
mTOR forms part of two different complexes, mTOR complex 1
(mTORC1) and mTORC2, which exert their actions by regulating a
number of important proteins.10 mTORC2 acts upstream and is
suggested to phosphorylate Akt, whereas mTORC1 acts
downstream of Akt.10
Insulin-like growth factor 1 (IGF-1)-mediated activation of Akt
has been reported to be dependent on lipid rafts.11,12 Rafts are
membrane microdomains highly enriched in cholesterol and
sphingolipids, which act as scaffolds for signaling pathways in the
cell membrane,13 and growing evidence shows their potential as
therapeutic targets in cancer therapy.14–23 An endogenous raft-
resident Akt has been reported in LNCaP human prostate cells that
showed a different substrate afﬁnity as compared with non-raft
Akt, suggesting the presence of distinct Akt populations with
differential signaling behavior.24
The synthetic antitumor lipids (ATLs) are a family of compounds,
initially synthesized as ether phospholipids and widely referred
to as alkyl-lysophospholipid analogs, which are able to selectively
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induce apoptosis in tumor cells.18,21,25–29 These ATLs include the
ether lipid edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-
phosphocholine) as well as perifosine (octadecyl-(1,1-dimethyl-
piperidinio-4-yl)-phosphate), which accumulate in lipid rafts,14,19,30
promote co-capping of Fas/CD95 death receptor and rafts,19,31,32
and inhibit PI3K/Akt survival signaling.32–34 Edelfosine shows
afﬁnity for cholesterol35,36 likely due to geometry compensation of
the ‘cone shape’ of sterols and the ‘inverted cone shape’ of
edelfosine that leads to a stable bilayer.36 In vivo and in vitro
experimental approaches have shown that ATLs selectively kill MCL
cells as well as additional hematological cancer cells, including
patient-derived primary cancer cells, by a lipid raft-dependent
mechanism.18,21,29
In this work, we provide evidence that MCL cell survival
depends on raft-mediated Akt activation for survival. We show
here that ATLs inhibit PI3K/Akt signaling by displacing Akt and key
enzyme regulators from lipid rafts, leading to Akt dephosphoryla-
tion and apoptosis. In contrast, Fas/CD95 death receptor was
recruited to rafts upon ATL treatment. Our data suggest that
raft environment is essential for Ser473 Akt phosphorylation in
MCL cells. ATL oral treatment inhibited MCL tumor growth in
xenograft animal models. Apoptosis induced by either edelfosine
or perifosine was not blocked by tumor microenvironmental
stimuli in MCL primary cultures and cell lines. These results




Edelfosine (Inkeysa, Barcelona, Spain) and perifosine (Zentaris, Frankfurt,
Germany) were prepared as 2-mM stock solutions in culture medium. Anti-
CD40 immunoglobulin was a kind gift from Francisco Lozano (Immunology
Department, Hospital Clı´nic-IDIBAPS, Barcelona, Spain). Caspase inhibitor
benzyloxycarbonyl-Val-Ala-Asp(OMe)-ﬂuoromethylketone (z-VAD-fmk)
(Enzo Life Sciences, Lausen, Switzerland) was prepared in dimethyl sulfoxide
as a 100-mM stock solution. Akt inhibitor 1/2, Akt inhibitor III, Akt inhibitor X
(Calbiochem/Merck, Darmstadt, Germany) and PI3K inhibitor wortmannin
(Cell Signaling, Irvine, CA, USA) were prepared in dimethyl sulfoxide as 10 and
2mM stock solutions. ERK inhibitor PD98059 and JNK inhibitor SP600125
(Calbiochem/Merck) were prepared as 10 or 20mM stock solutions in
dimethyl sulfoxide. Pervanadate was prepared by mixing orthovanadate and
H2O2 (Calbiochem/Merck) as previously described.
37
Cell culture
The human MCL cell lines Z-138, JVM-2, Jeko-1, HBL-2, as well as the
stromal HS-5 cell line were grown in RPMI-1640 culture medium
supplemented with 10% heat-inactivated fetal bovine serum, 2mM
L-glutamine, 100U/ml of penicillin and 100mg/ml streptomycin at 37 1C
in humidiﬁed 95% air and 5% CO2.
HS-5 coculture
A total of 2 105 HS-5 stromal cells were plated in 24-well plates and left
to attach overnight before adding 5 105 MCL patient-derived cells. ATLs
were added at 10 mM for 24 h, and then MCL cells were carefully collected
and analyzed by western blot or ﬂow cytometry.38
Isolation and culture of primary cells
Cells from nine patients diagnosed with MCL according to the World
Health Organization classiﬁcation criteria were studied. Informed consent
was obtained from each patient in accordance with the Ethics Committee
of the Hospital Clı´nic (Barcelona, Spain). Cells were cryopreserved in liquid
nitrogen in the presence of 10% dimethyl sulfoxide and 60% heat-
inactivated fetal bovine serum (Life Technologies, Carlsbad, CA, USA). MCL
primary cells were cultured immediately after thawing or isolation at a
concentration of 1–3 106 cells/ml in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 100U/ml
penicillin and 100mg/ml streptomycin at 37 1C in a humidiﬁed atmosphere
containing 5% CO2. Patient samples showed an enrichment of tumor cells
of at least 80%, as assessed by ﬂow cytometry detection of CD19þ /CD5þ
cells from whole peripheral blood mononuclear cells.
Apoptosis assay
Quantitation of apoptotic cells was calculated by ﬂow cytometry as the
percentage of cells in the sub-G0/G1 region (hypodiploidy) in cell cycle
analysis, as previously described.39
To analyze apoptosis by Annexin V labeling in MCL patient-derived
samples and cell lines, 5 105 cells were incubated for 24 h with the
indicated agents. Cells were then washed in Annexin V-binding buffer and
incubated in 50ml Annexin V-binding buffer with allophycocyanin-
conjugated anti-CD3 and phycoerythrin-conjugated anti-CD19 antibodies
(Becton Dickinson, San Jose, CA, USA) for 10min in the dark. Cells were
then diluted with Annexin V-binding buffer to a volume of 150ml and
incubated with 1 ml FITC-labeled Annexin V (Bender MedSystems, Vienna,
Austria) for 15min in the dark. A total of 10 000 stained cells were then
analyzed by ﬂow cytometry on a Becton Dickinson ﬂuorescence-activated
cell sorting (FACS) Calibur ﬂow cytometer using CellQuest software
(Becton Dickinson).
Cytoﬂuorimetric analysis of mitochondrial transmembrane
potential and generation of reactive oxygen species
To evaluate mitochondrial transmembrane potential (DCm) disruption and
the generation of reactive oxygen species, cells (106/ml) were incubated in
phosphate-buffered saline (PBS) with 20 nM 3,30-dihexyloxacarbocyanine
iodide [DiOC6(3)] (green ﬂuorescence) (Molecular Probes, Leiden, The
Netherlands) and 2 mM dihydroethidine (red ﬂuorescence after oxidation)
(Sigma, St Louis, MO, USA) for 40min at 37 1C, followed by analysis on a
FACSCalibur ﬂow cytometer, as previously described.39
Western Blot
Cells (4–5 106) were lysed with 60 ml lysis buffer (200mM HEPES, pH 7.5,
10mM EGTA, 40mM b-glycerophosphate, 1% (v/v) NP-40, 25mM MgCl2,
2mM sodium orthovanadate, 1mM DTT) supplemented with protease
inhibitors (1mM phenylmethanesulfonyl ﬂuoride, 20mg/ml aprotinin and
20mg/ml leupeptin). Proteins (40mg) were run on SDS-polyacrylamide gels
under reducing conditions, transferred to polyvinylidene ﬂuoride mem-
branes (Millipore, Billerica, MA, USA), blocked with 5% (w/v) defatted milk
powder in TBST (50mM Tris-HCl, pH 8.0, 150mM NaCl, 0.1% (v/v) Tween 20)
for 1 h at room temperature, and incubated for 1 h at room temperature or
overnight at 4 1C with speciﬁc antibodies (see Supplementary Information).
Antibody reactivity was monitored with horseradish peroxidase-conju-
gated anti-rabbit or anti-mouse IgG, using an enhanced chemilumines-
cence detection kit (GE Healthcare, Little Chalfont, UK).
Lipid raft isolation
Lipid rafts were isolated by using lysis conditions and centrifugation on
discontinuous sucrose gradients as previously reported.31 Twelve fractions
(1-ml each) were collected from the top of the gradient. To determine the
location of lipid rafts and distinct proteins in the discontinuous sucrose
gradient, 20 ml of the raft (fractions 4þ 5þ 6 of the sucrose gradient) and
non-raft (fractions 11þ 12 of the sucrose gradient) fractions were
subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted
as previously described.31 The location of GM1-containing lipid rafts was
determined using cholera toxin B subunit conjugated to horseradish
peroxidase (Sigma) (1:500 dilution in TBST) as previously described.31
Confocal microscopy
Serum-starved Z-138 cells (4 105), treated with or without pervanadate37
for 15min, were settled onto poly-L-lysine-coated slides, ﬁxed with 4%
formaldehyde and permeabilized for 1min with 0.1% Triton in PBS. Then,
cells were incubated with anti-Ser473 p-Akt rabbit polyclonal antibody
(Cell Signaling) (1:100 dilution in PBS/1% bovine serum albumin) at room
temperature, followed by incubation with CY3-conjugated sheep anti-
rabbit antibody (Jackson ImmunoResarch, West Groove, PA, USA) (1:150
dilution in PBS/1% bovine serum albumin) for 1 h at room temperature.
Then, nuclei were stained by addition of 2 ng/ml 40 ,6-diamidino-2-
phenylindole in PBS for 1min at room temperature. Samples were then
analyzed by confocal microscopy using a Leica confocal microscope
TCS-SP5 (Mannheim, Germany).
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Xenograft mouse model
Detailed information on the animal model experiments with CB17-severe
combined immunodeﬁcient mice inoculated subcutaneously into their
lower dorsum with the human MCL Z-138 cell line is included in
Supplementary Information.
Statistical analysis
Values are expressed as means±s.d. of the number of experiments
indicated. Between-group statistical differences were assessed using the
Student’s t-test. A P-value ofo0.05 was considered statistically signiﬁcant.
RESULTS
ATLs activate the intrinsic apoptotic signaling pathway and inhibit
Akt signaling in MCL cells
We have found that treatment of MCL cell lines Z-138, JVM-2 and
Jeko-1 with the ATLs edelfosine and perifosine induced mitochon-
drial transmembrane potential (DCm) disruption (Figure 1a) and
reactive oxygen species production (Supplementary Figure S1).
Caspase-9 activation was also detected in Z-138 cells after ATLs
incubation (Figure 1b). These events were related to the activation
of the intrinsic apoptotic signaling that eventually led to cell death
(Figures 1a and b and Supplementary Figures S1, S2A and S2B).
Mitochondrial depolarization was one of the ﬁrst events triggered
by ATLs, as this phenomenon was observed as soon as 6 h of
treatment (Supplementary Figure S2A) prior to the onset of
apoptosis after 24-h incubation, as assessed by an increase in the
percentage of sub-G0/G1 cell population (Supplementary Figure
S2B). The apoptotic response was caspase-mediated, as preincu-
bation with the cell-permeable pan-caspase inhibitor z-VAD-fmk
abrogated ATL-induced apoptosis (Supplementary Figure S3).
As inhibition of PI3K/Akt signaling has been linked to activation
of the intrinsic apoptotic pathway,7 we examined the time-
dependent effect of edelfosine, which displayed a higher in vitro
anti-MCL activity than perifosine (Supplementary Figure S2B),29
on Akt activation, Akt targets and related kinases. Whereas
1-O-octadecyl-rac-glycero-3-phosphocholine (ETOH), an inactive
edelfosine analog,25,40 neither induced apoptosis nor inhibited Akt
phosphorylation (Supplementary Figure S4), edelfosine-treated
cells showed a dramatic decrease of Ser473 p-Akt at very early
incubation times (3 h), followed by a reduction in Thr308 p-Akt
after 15-h incubation (Figure 1c). Using a speciﬁc antibody that
recognized p-Akt substrates with the motif RXRXXS/T,41 we
detected a decrease in the phosphorylation of most Akt
substrates after 3-h incubation (Figure 1c). However, the level of
Ser9/21 GSK3 phosphorylation was not inhibited, but slightly
activated, and Ser136 dephosphorylation of Bad was detected
after 24-h incubation with edelfosine (Figure 1c), when apoptosis
was already triggered (Supplementary Figure S2B). These results
are in line with our previous observation that MCL cell exposure to
ATLs did not modify the expression of cyclin D1,29 which is
physiologically targeted to proteasomal degradation by GSK3.4 In
addition, arguing in favor of an Akt-independent regulation of
GSK3 signaling in MCL cells, preincubation of Z-138 cells with the
GSK3 inhibitor lithium chloride potentiated ATL-induced apoptosis
(Figure 1d), suggesting that ATLs act through a signaling pathway
independent of GSK3.
We also analyzed the phosphorylation of mTOR that acts
downstream of Akt, forming the complex mTORC1.10 We found
that phosphorylation levels of mTOR (p-mTOR), as well as of its
direct substrate 4E-BP1 (p-4E-BP1), were rapidly decreased after
3-h incubation with edelfosine (Figure 1c). The time course
of this inhibition paralleled that of Ser473 p-Akt (Figure 1c).
Both mTOR and 4E-BP1 protein levels were diminished by the time
DNA degradation was triggered (Figure 1c and Supplementary
Figure S2B).
Next, we analyzed the levels of Ser473 p-Akt of distinct MCL cell
lines in relationship to their ATL sensitivity. We found that MCL cell
lines ranked HBL-244 Jeko-14Z-138EJVM-2 for their basal level
of phospho-Ser473 Akt (Figure 1e). This order was inversely
related to their sensitivity to ATLs, HBL-2 cells being resistant to
their apoptotic action (Figure 1e). Although ATLs induced a rapid
and complete dephosphorylation of Akt in Z-138-sensitive cell line
(Figure 1c), the high levels of p-Akt in ATL-resistant HBL-2 cells
were not decreased upon ATL treatment (Figure 1f). However, as
shown in Figure 1c and Supplementary Figure S5, we found a
decrease in Ser473 p-Akt levels after ATL incubation in Z-138,
JVM-2 and Jeko-1 MCL-sensitive cells after ATL incubation. These
data support the notion that the extent of ATL-induced apoptosis
in MCL cells is correlated with and depends on the Akt
phosphorylation status at Ser473, suggesting the involvement of
Akt dephosphorylation in the mechanism of ATL antitumor activity.
Effect of edelfosine on ERK and JNK phosphorylation in MCL cells
As JNK signaling has been involved in ATL-induced apoptosis40
and pathogenesis of MCL,42 and ERK activation has been
described as a possible compensatory mechanism in Akt-
compromised cells,43 we assessed the phosphorylation status of
ERK and JNK in Z-138 cells exposed to edelfosine. As shown in
Figure 2a, the level of p-JNK was dramatically increased during
edelfosine exposure, whereas the p-ERK level was not modiﬁed
during the ﬁrst 9 h of treatment, and then decreased following the
induction of apoptosis. However, despite p-JNK and p-ERK levels
could be efﬁciently inhibited by JNK inhibitor SP600125 and ERK
inhibitor PD98059, respectively (Figure 2b, and data not shown),
these latter inhibitors did not signiﬁcantly modify the cytotoxicity
of ATLs, as assessed by hypodiploidy or Annexin V analyses
(Figures 2c and d).
Altogether, our data suggested that ATL-induced apoptosis in MCL
cells involved a rapid and main Akt dephosphorylation at Ser473,
rather than at Thr308, with no signiﬁcant involvement of the Akt
targets, GSK3 and Bad, and independently of ERK and JNK signaling.
PI3K inhibition potentiates ATL-induced apoptosis
To further assess the involvement of PI3K/Akt signaling in MCL
sensitivity to ATLs, we preincubated MCL cells with the PI3K
inhibitor wortmannin before ATL addition. Preincubation of Z-138
cells with wortmannin for 1 h, followed by 24-h incubation with
perifosine or edelfosine, potentiated the effect of ATLs on the
inhibition of Akt and mTOR phosphorylation after a 6-h incubation
(Figure 2e) as well as on apoptosis induction (Figure 2f),
suggesting that inhibition of PI3K/Akt could increase the ATL-
mediated apoptotic response.
Akt inhibitors induce apoptosis in the Z-138 MCL cell line
Next, we examined the action of speciﬁc Akt inhibitors (Akti) as
apoptotic inducers in Z-138 cells, namely: Akti-1/2, an allosteric PH
domain-dependent inhibitor; Akt inhibitor III, a substrate-compe-
titive phosphatidylinositol ether analog and Akt inhibitor X, which
prevents phosphorylation of Akt and downstream targets44,45
(Figure 3a). All these Akt inhibitors decreased Ser473 Akt
phosphorylation as well as mTOR phosphorylation (Figure 3b,
inset), and induced apoptosis (Figure 3b) and DCm disruption
(Figure 3c) in Z-138 cells. In addition, the above Akt inhibitors
induced JNK activation and a slight increase in the level of JNK,
whereas GSK3 phosphorylation was not inhibited, but slightly
activated (Figure 3d). These data resemble those obtained with
ATLs (Figures 1c and 2a), suggesting that Akt inhibitors and ATLs
were targeting the same signaling pathway in MCL cells.
CD40 stimulation does not protect MCL cells from ATL cytotoxicity
The microenvironment, including cytokines, has a central role on
MCL cell survival and drug resistance, and the CD40 system acts as
a growth-promoting stimulus.4,46 In this regard, we preincubated
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MCL cell lines JVM-2 and Z-138 with anti-CD40 immunoglobulin
for 1 h, and then ATLs were added for 24 h before evaluating
apoptosis, as assessed by DNA degradation through cell cycle
analyses (Figure 4a). Pretreatment of MCL cells with anti-CD40
immunoglobulins did not prevent perifosine- or edelfosine-
induced apoptosis, and only a very slight decrease in the
Figure 1. Involvement of the intrinsic apoptotic pathway and Akt signaling in the action of ATLs on MCL cells. (a) Z-138, JVM-2 and Jeko-1 cells
were untreated (control) or treated with 10 mM perifosine or edelfosine for 24 h, and disruption of DCm [(DiOC6(3)
low)] is shown. Fluorescence
flow cytometry profiles shown are representative of three independent experiments. (b) Z-138 cells, untreated (control, C) or treated with
10mM perifosine (P) or edelfosine (E) for 12 h were analyzed by immunoblotting for anti-capase-9-active fragments. Immunoblotting for b-actin
was used as an internal control for equal protein loading in each lane. (c) Z-138 cells were untreated (control, C) or treated with 10 mM
edelfosine for the indicated times, and then analyzed by immunoblotting using specific antibodies against p-Akt (Ser473), p-Akt (Thr308), Akt,
p-Akt substrates (RXRXXS/T), p-mTOR, mTOR, p-4E-BP1, 4E-BP1, p-GSK3a/b, GSK3a/b, p-Bad (Ser136) and Bad. Immunoblotting for tubulin was
used as an internal control for equal protein loading in each lane. Representative blots of three separate experiments are shown. (d) Z-138
cells were preincubated without or with 20mM lithium chloride for 1 h, and then incubated in the absence (control) or presence of 10 mM
perifosine or edelfosine for 24 h, and analyzed by flow cytometry to evaluate apoptosis. Data shown are means±s.d. of three independent
experiments (*Po0.05; **Po0.01). The indicated statistically significant differences were between cells untreated and treated with lithium in
the different experimental conditions, but they are equally statistically significant when we subtract the apoptotic percentages of controls
with or without lithium from the respective ATL treatments. (e, upper) HBL-2, Jeko-1, JVM-2 and Z-138 cell lines were incubated without
(control) or with 10mM perifosine or edelfosine for 24 h, and analyzed by flow cytometry to evaluate apoptosis. Data shown are means±s.d. of
three independent experiments. (e, lower) MCL cell lines HBL-2, Jeko-1, JVM-2 and Z-138 were analyzed by immunoblotting for p-Akt (Ser473)
and b-actin. Blots were briefly exposed for autoradiography to highlight the high level of p-Akt in HBL-2 cells as compared with the other MCL
cell lines. (f ) HBL-2 cells were untreated (control, C) or treated with 10 mM perifosine (P) or edelfosine (E) for 6 h, and then analyzed by
immunoblotting with specific antibodies against p-Akt (Ser473), p-Akt (Thr308) and Akt. Representative blots of three separate experiments
are shown.
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ATL-induced apoptotic response was detected (Figure 4a). Pre-
treatment of MCL cells with anti-CD40 antibody increased Ser473
p-Akt level (Figure 4b), but ATLs induced Akt dephosphorylation in
both untreated and anti-CD40-treated cells (Figure 4b). These data
suggest that CD40 pro-survival signaling does not affect
signiﬁcantly the ATL proapoptotic activity in MCL cells. Similar
results were obtained by using Annexin V-binding assays to
quantify apoptotic cells (data not shown).
Localization of PI3K/Akt signaling in MCL cell lipid rafts
As the PI3K/Akt pathway is constitutively activated in MCL cells,4,5
and proper activation of Akt has been suggested to be dependent
on lipid rafts,11,12 we isolated lipid rafts from Z-138, JVM-2 and
Jeko-1 cells based on their insolubility in Triton X-100 lysis buffer
at 4 1C.14 GM1-containing lipid rafts were identiﬁed using cholera
toxin B cell subunit conjugated to horseradish peroxidase (Figures
5a and b). Raft and non-raft fractions, prepared as described in
Materials and methods, were analyzed. We observed that rafts
from untreated control Z-138 cells were highly enriched in a
subpopulation of Akt that was fully activated (Ser473 and Thr308
phosphorylation) (Figure 5a). Additional Akt-signaling regulatory
kinases were also detected in lipid rafts, including PI3K, PDK1 full-
active form (that is, phosphorylated on Ser241) and mTOR. Non-
phosphorylated Akt and PDK1, unlike their phosphorylated forms,
were equally distributed in raft and non-raft fractions (Figure 5a).
These data suggest that raft membrane domains can serve as the
key platforms for PI3K/Akt activation in MCL cells.
Regulation of raft-mediated Akt signaling is critical for MCL cell
survival
ATLs target lipid rafts and reorganize their protein composi-
tion.14,19,30 Following edelfosine incubation, we detected a
dramatic displacement of upstream Akt kinases PI3K and
p-PDK1, as well as mTOR to non-raft fractions (Figure 5a). Akt
was also partially displaced from raft fractions upon edelfosine
treatment (Figures 5a and b). Interestingly, we found that
edelfosine treatment inhibited p-Akt and the phosphorylation of
Akt downstream substrates present in the raft fractions of Z-138
Figure 2. Effect of ATLs on JNK and ERK signaling, and PI3K inhibition enhances ATL-induced cell death in Z-138 cells. (a) Cells were untreated
(control, C) or treated with 10 mM edelfosine for the indicated times, and then analyzed by immunoblotting for p-JNK, JNK, p-ERK and ERK2.
(b) Cells were preincubated without (control, C) or with 1 mM SP600125 (SP) for 1 h, and then incubated in the absence or presence of 10 mM
perifosine (P) or edelfosine (E) for 6 h, and analyzed by immunoblotting for p-JNK and JNK. (c) Cells were preincubated without or with 1 mM
SP600125 (SP) for 1 h, and then incubated in the absence or presence of 10 mM edelfosine (EDLF) for 24 h. Apoptosis was then quantitated as
the percentage of cells in the sub-G0/G1 region following cell cycle analysis by flow cytometry. Untreated control cells were run in parallel.
(d) Cells were preincubated without or with 20 mM PD98059 (PD) for 1 h, and then incubated with 10 mM perifosine (PRIF) or edelfosine (EDLF)
for 24 h. Cell viability was assessed as non-apoptotic cells in Annexin V-binding analysis by flow cytometry. Data are the means of two
independent experiments performed. (e) Cells were pretreated without (control, C) or with 400 nM wortamnin (WN), and then incubated with
10mM perifosine (P) or edelfosine (E) for 6 h and analyzed by immunoblotting for p-Akt (Ser473), Akt, p-mTOR and mTOR. (f ) Cells were
preincubated without or with 400 nM WN for 1 h, and then incubated in the absence or presence of 10 mM perifosine or edelfosine for 24 h, and
analyzed by flow cytometry to evaluate apoptosis. Data shown are means±s.d. (**Po0.01) or representative blots of three independent
experiments.
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Figure 3. Akt inhibitors induce apoptosis in Z-138 cells. (a) Molecular structures of the Akt inhibitors (Akti) tested in this study. (b) Cells were
incubated with Akt inhibitors for 24 h, and apoptosis was then quantitated by flow cytometry. Untreated control cells were run in parallel.
Data shown are means±s.d. of three independent experiments. (inset, left) Cells were untreated (control, C) or treated with 10 mM of each Akt
inhibitor for 6 h, and then analyzed by immunoblotting for p-Akt (Ser473), Akt, p-mTOR and mTOR. (inset, right) Bands from the above gel were
quantitated using ImageJ software and phosphorylated/total protein ratio values for p-Akt and p-mTOR relative expression levels were
calculated. (c) Cells were untreated (control) or treated with 10 mM Akti-1/2, Akti-III or Akti-X, and disruption of DCm [(DiOC6(3)
low)] was
measured as described in Materials and methods after 6-h incubation. Fluorescence flow cytometry profiles shown are representative of three
independent experiments. (d) Cells were untreated (control, C) or treated with 10 mM Akti-1/2, Akti-III or Akti-X for 24 h and then analyzed by
immunoblotting for p-JNK, JNK1, p-GSK3, GSK3 and b-actin (SDS 12% polyacrylamide gels). Immunoblotting for b-actin was used as an
internal control for equal protein loading in each lane. Representative blots of three separate experiments are shown.
Figure 4. ATL-induced apoptosis in MCL cells is independent of microenvironmental stimuli. (a) JVM-2 and Z-138 MCL cell lines were
preincubated without or with 500 ng/ml anti-CD40 antibody, and then incubated in the absence or presence of 10 mM perifosine (PRIF) or
edelfosine (EDLF). After a 24-h treatment, apoptosis was then quantitated by flow cytometry. Untreated control cells were run in parallel. Data
shown are means±s.d. of three independent experiments. (b) Z-138 cells were pretreated without (control, C) or with 500 ng/ml anti-CD40
antibody, and then incubated with 10 mM perifosine (P) or edelfosine (E) for 6 h, and analyzed by immunoblotting with specific antibodies
against p-Akt (Ser473) and Akt. Immunoblotting for b-actin was used as an internal control for equal protein loading in each lane.
Representative blots of three separate experiments are shown.
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Figure 5. Involvement of raft-mediated Akt signaling in edelfosine-induced apoptosis in MCL cells. (a) Z-138 cells untreated (control) and
treated with 10mM edelfosine (EDLF) for 15 h were lysed in 1% Triton X-100 and fractionated by centrifugation on a discontinuous sucrose
density gradient. Equal volumes of collected raft (R) and non-raft (NR) fractions were subjected to SDS-polyacrylamide gel electrophoresis
before analysis of the indicated proteins using specific antibodies. The migration positions of PI3K, mTOR, p-PDK1 (Ser241), PDK1, p-Akt
(Thr308), p-Akt (Ser473), Akt, p-Akt substrate (RXRXXS/T) and Bad were examined by immunoblotting using specific antibodies. Location of
GM1-containing lipid rafts was determined using cholera toxin (CTx) B subunit conjugated to horseradish peroxidase. (b) JVM-2 and Jeko-1
cells untreated (control) and treated with 10 mM edelfosine (EDLF) for 15 h were fractionated as above to isolate raft (R) and non-raft (N-R)
fractions. The migration positions of p-Akt (Ser473), Akt and p-Akt substrates (RXRXXS/T) were examined by immunoblotting. Location of
GM1-containing lipid rafts was determined using CTx B subunit conjugated to horseradish peroxidase. (c) Serum-starved Z-138 cells untreated
(control) or treated with pervanadate (PERV) for 15min were incubated with anti-p-Akt (Ser473) antibody, and then with CY3-conjugated
secondary antibody (red fluorescence) and 40,6-diamidino-2-phenylindole (blue fluorescence), as described in Materials and methods. Bar,
10mm. (d) Z-138 cells were preincubated without (control) or with pervanadate (PERV) for 15min at 37 1C, and then incubated in the absence
or presence of 10 mM edelfosine (EDLF) for 24 h to evaluate apoptosis induction by flow cytometry (d, upper), or in the presence of 10 mM
edelfosine (EDLF) for 6 h to analyze p-Akt (Ser473) and Akt protein levels by immunoblotting (d, lower). (e, upper) Z-138 and JVM-2 cells were
untreated (control) or incubated with 10 mM edelfosine (EDLF) or perifosine (PRIF) for 15 h, and then raft and non-raft fractions were obtained
as above, and analyzed for Fas/CD95 using specific antibodies. (e, lower) Z-138 cells were preincubated for 1 h with edelfosine (EDLF), followed
by treatment with 50-ng/ml CH-11 for 48 h, and then apoptosis was quantitated by flow cytometry. Data shown are means±s.d. or
representative of three independent experiments performed. Asterisks indicate values that are significantly different from untreated control
cells at Po0.01 (**) level by Student’s t-test.
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Table 1. Characteristics of MCL patients and cytotoxic action of ATLs
Patient nos. Age/gender Disease status % tumor cellsa P53 statusb Perifosine LD50 at 24 h (mM) Edelfosine LD50 at 24 h (mM)
MCL no. 1 64/M Relapse 95 del/mut 18.2 6.2
MCL no. 2 79/M Diagnosis 85 wt 8.8 6.6
MCL no. 3 57/F Diagnosis 95 wt 3.7 2.1
MCL no. 4 81/M Diagnosis 88 del/mut 7.4 4.0
MCL no. 5 76/M Diagnosis 69 del/mut 7.2 4.1
MCL no. 6 77/M Diagnosis 80 wt 18.5 14.0
MCL no. 7 70/M Relapse 70 wt 13.8 16.8
MCL no. 8 76/M Diagnosis 83 wt Not reached Not reached
MCL no. 9 85/M Diagnosis 85 wt Not reached Not reached
Abbreviations: ATL, antitumor lipid; M, male; F, female; del, deleted; mut, mutated; wt, wild-type; LD50, drug concentration that kills 50% of the cell population.
a% of CD19-positive tumor cells quantified by flow cytometry. bP53 mutational status assessed by fluorescent in situ hybridization and direct sequencing.
Figure 6. In vivo anti-MCL activity of edelfosine and perifosine, and effect of ATLs on MCL patient-derived cells. (a) CB17-severe combined
immunodeficient mice were inoculated subcutaneously with 107 Z-138 cells, and once palpable tumors were detected, mice were orally
treated with vehicle (control), 30mg/kg edelfosine (EDLF) and 26.45mg/kg perifosine (PRIF) for 3 weeks. Tumor size was recorded at the
indicated times during drug treatment. (b) After completion of the in vivo assay, control mice and animals treated with edelfosine (EDLF) or
perifosine (PRIF) were killed, and tumors were isolated and measured (weight and volume). Data in (a) and (b) are shown as mean values±s.d.
(n¼ 7). Asterisks indicate significant differences with respect to drug-free control values, at *Po0.05 and **Po0.01. (c) A notable reduction in
tumor size was observed after edelfosine or perifosine treatment. (d) Isolated primary tumor MCL cells from nine patients were treated with
10mM perifosine or edelfosine for 24 h. Non-apoptotic cells were quantified as Annexin V-negative cells by flow cytometry, as described in
Materials and methods. Untreated controls were run in parallel, and data are represented as percentage of cell viability (means of two
experiments) with respect to each untreated control. (e) MCL cells derived from patient no. 3, showing high-sensitivity to ATLs, and from
patient no. 8, showing low sensitivity to ATLs, were incubated without (control, C) or with 10 mM perifosine (PRIF) or edelfosine (EDLF) for 6 h,
and then analyzed by immunoblotting for p-Akt (Ser473) and Akt.
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cells (Figure 5a). Bad was mainly localized in non-raft fractions
(Figure 5a), suggesting that its inhibition occurs at a later stage as
shown in Figure 1c. Ser473 p-Akt was also inhibited in the raft
fractions of the JVM-2 and Jeko-1 cell lines, together with a
displacement of Akt from raft fractions (Figure 5b). These data
suggest that edelfosine incorporation in rafts blocks PI3K/Akt
signaling by displacing Akt and its regulators from rafts.
Next, we examined the subcellular localization of Ser473 p-Akt
by immunoﬂuorescence imaging of Z-138 cells treated with
pervanadate, the most potent known Akt activator,47 in order to
facilitate p-Akt visualization in the cell. Under basal conditions,
localization of p-Akt was difﬁcult to detect, but p-Akt Ser473 was
readily visualized at the cell plasma membrane following
pervanadate treatment (Figure 5c). Preincubation of MCL cells
with pervanadate allowed to overcome edelfosine-mediated
inhibition of Ser473 p-Akt and to abrogate, almost totally, the
apoptotic effect of edelfosine (Figure 5d), thus supporting that
membrane p-Akt downregulation is a crucial step in ATL-mediated
cell death. In addition, we found that incubation of MCL cells with
both edelfosine and perifosine induced recruitment of Fas/CD95
death receptor to rafts (Figure 5e). Thus, ATLs displaced survival
Akt signaling from rafts, whereas apoptotic Fas/CD95 death
receptor was translocated to these membrane domains. However,
despite Fas/CD95 translocation to rafts, when we incubated Z-138
cells with agonistic cytotoxic CH-11 anti-Fas monoclonal antibody
following edelfosine pretreatment, only a slight increase in
apoptosis was detected, which was not statistically signiﬁcant
when compared with cells treated only with the ether lipid
(Figure 5e). This lack of sensitization to the subsequent activation
of Fas/CD95 receptor was also found by using recombinant
human FasL/DC95L (data not shown).
In vivo efﬁcacy of edelfosine and perifosine in MCL treatment
By using a xenograft MCL-bearing CB17-severe combined
immunodeﬁcient mouse model, we found that daily oral
treatment for 3 weeks with ATLs (30mg/kg edelfosine, molecular
mass, 523.70g/mol; 26.45mg/kg perifosine, molecular mass,
461.67 g/mol) inhibited the growth of MCL cells. Serial caliper
measurements were made to determine tumor growth, and showed
a signiﬁcant anti-MCL activity for both ATLs (Figure 6a). A comparison
of tumors, isolated from drug-free control and ATL-treated MCL-
bearing mice, at the end of treatment rendered a dramatic reduction
of tumor weight and volume in mice treated with edelfosine or
perifosine (Figures 6b and c). These results highlight the effectiveness
of both edelfosine and perifosine in treating MCL in mice. No
signiﬁcant differences in mean body weight were observed between
drug-treated and control animals during the in vivo assay (3–7% of
Figure 7. Schematic model of raft-mediated Akt signaling in the regulation of cell survival and death in MCL cells during edelfosine treatment.
This scheme highlights the importance of lipid raft membrane domains for PI3K/Akt pathway activation in the regulation of MCL cell survival
or death, based on the data reported here. For further details, see the text.
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body weight loss in the treated groups versus control groups),
suggesting a low toxicity exerted by these two ATLs. This observation
is in agreement with a previous report showing lack of signiﬁcant
toxicity of edelfosine in a rat model.48
ATLs induce Akt inhibition and cell death in MCL patient-derived
cells
In an attempt to extrapolate the above data to patient-derived
cells, primary samples from nine MCL patients (Table 1) were
incubated for 24 h with the ATLs perifosine and edelfosine
at concentrations ranging from 1 to 50 mM, and cell viability
was determined by cytoﬂuorimetric quantiﬁcation of Annexin
V-negative cells. LD50 values for perifosine and edelfosine were
then calculated. As shown in Table 1, we observed a great
variability in the capacity of ATLs to promote cell killing of MCL
primary cultures, seven out of nine primary cultures being
sensitive to ATL concentrations below 20mM, whereas two cases
(nos. 8 and 9) were resistant to 50 mM ATL. Concentrations of ATLs
as low as 10mM induced a remarkable cytotoxicity (between 25
and 95%) in most of the patient-derived tumor cells (Figure 6d).
ATL cytotoxicity was closely linked to Akt dephosphorylation, as
shown by comparing ATL-sensitive with ATL-resistant MCL cells
(Figure 6e). We also cocultured primary patient-derived MCL cells
with the human bone marrow stromal cell line HS-5, which has
been reported to be tumor cell-protective against spontaneous
and drug-induced apoptosis38 in the absence or presence of
edelfosine or perifosine, and stroma-related protection toward
spontaneous and ATL-induced apoptosis was evaluated. About
60–70% of spontaneous tumor cell apoptosis was reversed by
MCL coculture with HS-5 cells, but this value decreased to 25–35%
in the presence of perifosine or edelfosine, thus suggesting that
the presence of stroma did not prevent the killing of MCL patient-
derived cells by ATLs.
DISCUSSION
Here, we have found for the ﬁrst time the presence of the PI3K/Akt
signaling pathway in the lipid rafts of MCL cells, and provide
evidence for the critical role of raft-mediated PI3K/Akt signaling in
MCL cell survival. Oral treatment with the ATLs edelfosine and
perifosine at an equimolar concentration of 57.3 mmol/kg body
weight achieved a strong anti-MCL activity in xenograft animal
models, and the killing activity of ATLs was not prevented by
tumor microenvironment stimuli. Our ﬁndings suggest that a
major event in the ATL-induced cell death in MCL cells lies in the
displacement of Akt and its upstream regulators PI3K, p-PDK1 and
mTOR from lipid rafts. Figure 7 depicts a plausible model for the
role of raft-mediated Akt activation in the control of cell survival
and in the mechanism of action of edelfosine-induced apoptosis
in MCL cells, based on the results reported here. Edelfosine has
been shown to accumulate in cholesterol- and sphingolipid-rich
rafts, in part, due to its high afﬁnity for cholesterol.35,49 According
to our model (Figure 7), the interaction of edelfosine with lipid
rafts would launch the following sequence of events, leading
eventually to apoptosis: edelfosine incorporation into rafts-
displacement of Akt and the kinases PI3K, PDK1 and mTOR from
rafts-inhibition of Akt phosphorylation-inhibition of Akt
substrate phosphorylation-loss of mitochondrial potential-
DNA degradation.
The Akt pathway has been shown to affect the intrinsic
apoptotic pathway through inhibition of proapoptotic proteins by
phosphorylation of Bad and caspase-9 on Ser136 and Ser196,
respectively.7,50 Here, we found that incubation of ATLs with MCL
cells led to caspase 9 activation, DCm loss and reactive oxygen
species production, compatible with an effect of ATLs on the
mitochondrial intrinsic pathway. As there is an apparent
connection between the extrinsic and intrinsic apoptotic
pathways through lipid rafts,51,52 the action of ATLs on the
intrinsic signaling route could be secondary to the action of ATLs
on lipid rafts. Inhibition of the PI3K/Akt pathway can induce
apoptosis in tumor cells through the recruitment of death
receptors to lipid rafts.32 In this regard, we found that ATL
treatment in MCL cells displaced Akt signaling from rafts, whereas
it recruited Fas/CD95 death receptor to the rafts. Inhibition of Bad
phosphorylation by ATLs was detected after rather long
incubation times, and was concomitant with the triggering of
apoptosis. This raises some doubts on the role of Bad in ATL-
mediated apoptosis in MCL cells, either as a cause or consequence
in the apoptotic response. In this regard, PI3K/Akt-dependent
survival in hematopoietic cells has been suggested to proceed
independently of Bad phosphorylation.9 Lipid rafts have been
shown to act as scaffolds for the recruitment of Fas/CD95 death
receptor and downstream signaling molecules, having a major
role in the killing activity of ATLs against a number of
hematological malignancies, including MCL.14,21,29,31 Thus, the
action of ATLs on raft membrane domains leads to the inactivation
of Akt survival signaling and activation of death receptor
apoptotic signaling. However, we did not detect a statistically
signiﬁcant sensitization of MCL cells to the subsequent agonistic
activation of Fas/CD95 receptor. Previous reports have shown a
deﬁcient apoptotic response to the external stimulation of Fas/
CD95 by agonistic anti-Fas/CD95 antibodies or FasL/CD95L in
tumor B cells.53,54 In this regard, it is interesting to note that unlike
the natural ligand Fas/CD95L or agonistic anti-Fas/CD95
antibodies that act through their interaction with the
extracellular portion of the Fas/CD95 receptor, edelfosine
induces activation of Fas/CD95 from within the cell in a FasL/
CD95L-independent manner.14,26,55 In fact, our previous data
suggest that edelfosine is even more efﬁcient than FasL/CD95L in
promoting apoptosis through the activation of Fas/CD95 by its
recruitment in membrane rafts enriched in downstream signaling
molecules,14,18,26,55 leading to the formation of clusters of
apoptotic signaling-molecule-enriched rafts,14,18,19,51 named
CASMERs,15,20,23,51 which could trigger an apoptotic response in
the absence of death receptor ligand. Thus, edelfosine could
promote Fas/CD95 activation, although the receptor is hardly
triggered by its natural ligand or agonistic antibodies. This could
explain the herein reported lack of signiﬁcance that leads to
further sensitization of MCL cells to FasL/CD95L or agonistic
antibodies after edelfosine treatment.
Although ATLs inhibited PI3K/Akt pathway, inducing depho-
sphorylation of Akt and downstream substrates, we failed to
detect dephosphorylation of GSK3, a typical substrate of Akt, thus
suggesting that the raft-mediated PI3K/Akt pathway can act
independently of GSK3 in this case. In this context, GSK3 has also
been shown to be regulated by phospholipase C/protein kinase C
in B cells.56 The fact that the GSK3 inhibitor lithium potentiates
ATL-induced apoptosis further suggests that ATLs act through a
GSK3-independent pathway. In prostate carcinoma cell lines,
overexpression of myristoylated Akt, which bypasses the
requirement for PH domain-mediated membrane recruitment,
abrogated perifosine effects.57 This oncogenic myristoylated Akt
has been reported to be located in rafts, displaying no GSK3
afﬁnity and a distinct substrate preference as compared with
cytosolic non-raft Akt.24 Thus, the results reported here suggest
that ATLs inhibit raft-mediated Akt that might regulate apoptosis,
but not GSK3 phosphorylation. On these grounds, our ﬁndings
suggest that part of the tumor traits of MCL cells could depend on
the raft-located Akt signaling pathway that shows a particular
substrate proﬁle, and could be exacerbated by pervanadate-
mediated activation. Our data suggest that ATL resistance in MCL
seems to be related to raft-dependent Akt activation and
overexpression.
Speciﬁc Akt inhibitors, with different molecular structures and
targeting distinct parts of the Akt molecule, reproduced ATL-
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mediated apoptotic events, suggesting that they target the same
Akt signaling crucial for MCL cell survival as ATLs. Interestingly, Akt
inhibitor III has a similar structure to edelfosine, but replacing the
choline group for inositol (Figure 3a). These data further support
the involvement of PI3K/Akt pathway in MCL cell survival.
As lipid rafts are known to be enriched in PI(4,5)P2 and
PI(3,4,5)P3,58 they provide a permissive milieu for the interaction
between PDK1 and Akt. ATLs have been found to accumulate in
lipid rafts in a number of hematological malignancies, altering the
raft protein and lipid composition.14,18 Thus, it is tempting to
envisage that ATLs might inhibit proteins with PH domains. The
levels of phosphatidylinositol-4,5-bisphosphate and Ser473
phosphorylation are more predictors of Akt activation state than
Thr308 phosphorylation.9 In this regard, Ser473 phosphorylation
of Akt seems to be more dependent on its location in lipid rafts,
and to have a critical role in Akt activation. In fact, Akt Ser473
kinase activity has been associated to plasma membrane rafts.59
These data support the results reported here of a rapid inhibition
of Ser473 p-Akt following ATL action in MCL cells, whereas
inhibition of Thr308 p-Akt was a secondary effect that required
longer ATL incubation times. Likewise, higher levels of Ser473
p-Akt than Thr308 p-Akt have been shown in mouse lymphoma
ATL-resistant cells.60 Taking together, these data implicate a
critical role for lipid rafts in Ser473 Akt phosphorylation in MCL. In
this regard, we found a dramatic displacement from rafts of mTOR
(Figure 5a), which could form the complex mTORC2, suggested to
be PKD2, involved in the Ser473 phosphorylation of Akt,10
following edelfosine treatment. Thus, ATLs might inhibit the
PI3K/Akt signaling pathway at the very early stages of the route
leading to the series of downstream events reported here. Our
data highlight raft-mediated PI3K/Akt signaling as a major target
in MCL therapy, thus supporting a new raft-mediated strategy for
MCL treatment. Inhibition of raft-mediated PI3K/Akt signaling
could lead to a decreased apoptotic threshold and to the
induction of apoptosis.
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